<DOC>
	<DOCNO>NCT00930319</DOCNO>
	<brief_summary>Effectiveness Safety Firmagon® Androgen Ablative Therapy Advanced Hormone-dependent Prostate Carcinoma . The period Prostate Specific Antigen ( PSA ) progression Firmagon® therapy document related testosterone value measure course therapy ( available ) . Other clinical parameter , patient ' quality life direct indirect cost incur medical care advance hormone-dependent prostate carcinoma consequence evaluate . In context medical outcome life quality define effectiveness benefit value parameter . Both effectiveness daily life circumstance economic variable therapy thus show compare within analysis cost vs. benefit cost vs. effectiveness .</brief_summary>
	<brief_title>Effectiveness Safety Firmagon®</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>therapeutic need accord SPC write informed consent contraindication accord SPC</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>